Navigation Links
Cerulean Pharma's Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
Date:11/19/2012

http://www.clinicaltrials.gov/">www.clinicaltrials.gov.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs. With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at http://www.ceruleanrx.com.

Media Contacts:
Schwartz MSL
Benjamin Navon/Kathy Vigneault
cerulean@schwartzmsl.com
+1 781-684-0770

 


'/>"/>
SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
2. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
5. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
8. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
11. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... China , July 30, 2015 Tianyin ... a pharmaceutical company that specializes in the patented biopharmaceutical, ... pharmaceutical ingredients (API), provided updates regarding the notice it ... LLC (the "Exchange") indicating that the Company was below ... forth in Sections 134 and 1101 of the NYSE ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Robert Mazzacavallo has joined Veridiam as the company,s Chief ... of high-precision, fabricated assemblies and metal components, primarily serving ... aerospace and general industrial markets. , Before joining Veridiam, ... Camas, WA. At C-Tech, Bob worked closely with ...
... 3 Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... will host a conference call on Thursday, November 12, ... financial and operating performance for the first quarter ended ... product development and marketing activities. , Corgenix invites all ...
Cached Medicine Technology:Veridiam Names Robert Mazzacavallo New CFO 2
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... ... 2015 , ... Girl Scouts of Historic Georgia and Peach State Health Plan ... "Be a Friend First" program. Representatives from Peach State Health Plan presented a $10,000 ... Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We ...
(Date:7/31/2015)... , ... July 31, 2015 , ... BioViva USA, Inc. ... way we treat aging diseases. , BioViva announces it has begun a fundraiser ... with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the ...
(Date:7/31/2015)... Calgary, AB (PRWEB) , ... July 31, 2015 , ... ... changes. "When patients don't experience angina until a heart rate of 150 beats versus ... Fit Clinic in Calgary. "We are able to give life back to patients with ...
Breaking Medicine News(10 mins):Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... for majority of patients, survey found , WEDNESDAY, Aug. ... associated with neck problems, according to the results of ... aged 25 to 78, who had two types of ... (spine fusion). , Before the surgery, 86.4 percent of ...
... , NEW YORK, Aug. 12 ... of Ogilvy Healthworld North America, have been appointed Joint Worldwide CEOs ... Young. , , In making the announcement, Mr. ... they are also very complementary individuals. Their joint mandate is ...
... ... business culture and long history of technology innovation to enhance research, development and innovation ... Scottsdale, AZ ... management and security, today announced the expansion of its global operations with the opening ...
... Aug. 12 With obesity now the greatest threat to the health ... than ever. According to a new study in the August 2009 ... American Dietetic Association , portion and calorie-controlled meal replacements used in ... , , The st u ...
... SWARTZ CREEK, Mich., Aug. 12 Diplomat Specialty Pharmacy announced today they ... Inc.,s annual ranking of the fastest-growing private companies in America. ... is an amazing achievement, the additional details are even more resounding," stated Phil ... , , , Of the 43 ...
... , , DANA POINT, Calif., Aug. ... have selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler ... looking for a longer lasting dermal filler. Drs. Kofford have been ... success and effectiveness for the correction of wrinkles. , ...
Cached Medicine News:Health News:Surgery for Neck Pain May Also Relieve Headaches 2Health News:Joint Worldwide CEO's of Ogilvy Healthworld Named 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 3Health News:New Published Diet Study Reveals Meal Replacements as Top Strategy for Weight Loss 2Health News:Diplomat Specialty Pharmacy Honored By Inc. Magazine As One Of The Nation's Fastest-Growing Companies 2Health News:Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3
... 3200 sets a benchmark of innovative, ... for WBC, RBC, PLT and Reticulocyte ... needs of today's laboratory. The instrument ... analysis, automated sample handling, comprehensive data ...
... Data Management System provides comprehensive program management ... and the Precision PCx. The QC Manager ... collect, analyze, and report quality control data ... essential laboratory tool for managing data and ...
... The CELL-DYN SMS consistently produces high-quality ... ensuring consistent blood films every time, eliminating ... with significantly high or low hematocrit values. ... autoloader mixes, identifies the sample, and aspirates ...
... The QuickVue In-Line Strep A Test allows for ... directly from patient throat swab specimens. , ,QuickVue ... and is the first strep A test waived ... rapid procedure allow testing to take place at ...
Medicine Products: